Archives of Gynecology and Obstetrics

, Volume 259, Issue 3, pp 117–123 | Cite as

Serum CA 125 levels and survival in advanced ovarian cancer

  • K. Münstedt
  • M. Krisch
  • S. Sachsse
  • H. Vahrson
Originals

Abstract

We made a retrospective analysis of 85 patients with elevated serum CA 125 after surgery for ovarian cancer. Absolute CA 125 serum levels were a poor guide to prognosis. However, the ratio between the serum CA 125 after the first, second, or third course of treatment and the postoperative value was an excellent guide to prognosis. These were also independent and stable in the Cox Regression analysis.

Key words

CA 125 Prognostic factors Ovarian cancer Survival 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alagoz T, Buller RE, Berman M, Anderson B, Manetta A, DiSaia P (1994) What is a normal CA 125 level? Gynecol Oncol 53:93–97PubMedCrossRefGoogle Scholar
  2. 2.
    Avall-Lundquist E, Sjövall K, Hansson L-O, Eneroth P (1992) Peri-and postoperative changes in serum levels of four tumor markers and three acute phase reactants in benign and malignant gynecological diseases. Arch Gynecol Obstet 251:69–78Google Scholar
  3. 3.
    Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331–1337PubMedCrossRefGoogle Scholar
  4. 4.
    Bast RC, Klug TL, John ES, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC (1983) A radioimmunoassay using monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883–887PubMedCrossRefGoogle Scholar
  5. 5.
    Beattie GJ, Sturgeon C, Fisken J, Roulston JE (1993) The effect of surgery on the concentration of CA 125 in epithelial ovarian cancer. Ann Clin Biochem 30:402–403PubMedGoogle Scholar
  6. 6.
    Breitenecker G, Neunteufel W, Bieglmayer C, Kolbl H, Schieder K (1989) Comparison between tissue and serum content of CA 125, CA 19-9, and carcinoembryonic antigen in ovarian tumors. Int J Gynecol Pathol 8:97–102PubMedCrossRefGoogle Scholar
  7. 7.
    Burg MEL van der, Lammes FB, Verweij J (1992) CA 125 in ovarian cancer. Neth J Med 40:36–51PubMedGoogle Scholar
  8. 8.
    Canney PA, Moore M, Wilkinson PM, James RD (1993) Ovarian cancer antigen CA 125. A prospective clinical assessment of its role of a tumor marker. Br J Cancer 50:765Google Scholar
  9. 9.
    Crombach G, Würz H (1985) Vergleichende Bestimmung von CA 125, TPA und CEA bei Patienten mit malignen epithelialen Ovarialtumoren. In: Greten H, Klapdor R (Hrsg) Neue tumorassoziierte Antigene. Thieme, Stuttgart pp 167Google Scholar
  10. 10.
    Fisken J, Leonhard RCF, Stewart M, Beattie GJ, Sturgeon C, Aspinall L, Roulston JE (1993) The prognostic value of early CA 125 serum assay in epithelial ovarian carcinoma. Br J Cancer 68:140–145PubMedGoogle Scholar
  11. 11.
    Hawkins RE, Roberts K, Wiltshaw E, Mundy J, Fryatt IJ, McCready VR (1989) The prognostic significance of the half-life serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynecol 96:1395–1399Google Scholar
  12. 12.
    Kenemans P, Verstraeten AA, van Kamp GJ, Hilgers J (1994) CA 125 in the management of ovarian carcinoma (abstract #562). Ann Oncol 5:112Google Scholar
  13. 13.
    Kimura E, Murae M, Takanashi H, Yasuda M, Terashima Y, Furukawa T (1995) A multivariate analysis of serum CA 125 in patients with ovarian carcinoma: when should we measure it to predict prognosis? (Abstract # 56). Proc Annu Meet Am Soc Clin Oncol 14:89Google Scholar
  14. 14.
    Lavin PT, Knapp RC, Malkasian G, Whitney CW, Berek JC, Bast JC (1987) CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 69:223–227PubMedGoogle Scholar
  15. 15.
    Liu PY, Alberts DS, Federico M, Hanningan EV, Garcia DJ, Rothenberg ML, Dorr AT (1995): CA 125 concentration 8 weeks after treatment initiation independently predicts survival in patients with advanced epithelial ovarian cancer (abstract # 735). Proc ASCO 14:226Google Scholar
  16. 16.
    Makar A, Kristensen GB, Kaern J, Bormer OP, Abeler VM, Trope CG (1992) Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol 79:1002–1010PubMedGoogle Scholar
  17. 17.
    Mogensen O, Brock A, Nyland MH (1993) CA 125 measurements in ovarian cancer patients during their first postoperative week. Int J Gynecol Cancer 3:54–56PubMedCrossRefGoogle Scholar
  18. 18.
    Münstedt K, Vahrson H (1995) Efficacy of combined radio- and chemotherapeutic treatment of advanced ovarian cancer. Eur J Gynaecol Oncol 16:174–180PubMedGoogle Scholar
  19. 19.
    Pujade-Lauraine E, Piccart M, Rustin G, Lhommé C, Gore G, Ten Bokkel Huinink M, Fumoleau P, Oosterom A van, Kaye S, Belpomme D, Van Glabbeke M, Wander J, Chevallier B, Franklin H, Verweij J (1994) Comparison of CA 125 kinetics and WHO criteria to evaluate chemotherapy response (Abstract # 502). Ann Oncol 5:100Google Scholar
  20. 20.
    Redman CWE, Blackledge GR, Kelly K, Powell J, Buxton EJ, Luesley DM (1990) Can early serum CA 125 resonse predict outcome in epithelial ovarian cancer? Eur J Cancer 26:593–596PubMedCrossRefGoogle Scholar
  21. 21.
    Ron IG, Inbar M, Gelernter I, Lewysohn O, Ayalon D, Dale J, Chatchik S (1994) Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma. Acta Obstet Gynecol Scand 73:658–662PubMedGoogle Scholar
  22. 22.
    Rosen A, Sevelda P, Klein M, Spona J, Beck A (1990) A CA 125 score as a prognostic index in patients with ovarian cancer. Arch Gynecol Obstet 247:125–129PubMedCrossRefGoogle Scholar
  23. 23.
    Rustin G, Gennings JN, Nelstrop AE, Covarrubias H, Lambert HE, Bagshawew KD (1989) Use of CA-125 to predict survival of patients with ovarian carcinoma. J Clin Oncol 7: 1667–1671PubMedGoogle Scholar
  24. 24.
    Sevelda P, Schemper M, Spona J (1989) CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol 161:1213–1216PubMedGoogle Scholar
  25. 25.
    Vahrson H, Dolzycki E, Münstedt K (1993) Postoperative Strahlentherapie des Ovarialkarzinoms. In: Künzel W, Kirschbaum M (Hrsg) Gießener Gynäkologische Fortbildung. Springer, Berlin Heidelberg New York, S 287ffGoogle Scholar
  26. 26.
    Welander CE (1992) What do CA 125 and other antigens tell us about ovarian cancer biology? Acta Obstet Gynecol Scand 155:85–93Google Scholar
  27. 27.
    Yedema CA, Kenemans F, Voorhorst F, Bon G, Schijf C, Beex L, Verstraeten A, Hilgers J, Vermorken J (1993) CA 125 half-life in ovarian cancer: a multivariate survival analysis. Br J Cancer 67:1361–1367PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • K. Münstedt
    • 1
  • M. Krisch
    • 1
  • S. Sachsse
    • 1
  • H. Vahrson
    • 1
  1. 1.Department of Gynaecologic Oncology and RadiotherapyJustus-Liebig-University GießenGießenGermany

Personalised recommendations